Category
Diseases
Disease-area coverage across oncology, infectious disease, rare conditions, metabolic and cardiovascular disease and more — focused on the evidence, the treatments and the access questions in each.
583 articles in this topic.
Articles in this category

11/17/2026
Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion
The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
11/17/2026
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
The CHMP has recommended povorcitinib for hidradenitis suppurativa as Povofortay, a JAK1 inhibitor for adults who responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy.
Read Article →
11/17/2026
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
11/17/2026
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows
EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.
Read Article →
11/16/2026
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
11/16/2026
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
11/16/2026
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
11/13/2026
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
11/13/2026
ACS Updates Prostate Cancer Screening Guideline for PSA Testing
"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer
Read Article →
11/12/2026
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →
11/10/2026
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1
Read Article →
11/10/2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →


